[{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"XAF5","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"XAF5","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"scPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de Granada","sponsor":"Puleva Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Universidad de Granada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de Granada \/ Puleva Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Universidad de Granada \/ Puleva Biotech"},{"orgOrder":0,"company":"Af?liated Hospital of North Sichuan Medical College","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Af?liated Hospital of North Sichuan Medical College","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Af?liated Hospital of North Sichuan Medical College \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Af?liated Hospital of North Sichuan Medical College \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Sichuan Provincial People's Hospital","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Sichuan Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Provincial People's Hospital \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Sichuan Provincial People's Hospital \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Albert Einstein Healthcare Network \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"AstraZeneca | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly"},{"orgOrder":0,"company":"Isfahan University of Medical Sciences","sponsor":"Adibvira","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRAN","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Isfahan University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isfahan University of Medical Sciences \/ Adibvira","highestDevelopmentStatusID":"9","companyTruncated":"Isfahan University of Medical Sciences \/ Adibvira"},{"orgOrder":0,"company":"Bergman Clinics","sponsor":"Zimmer Biomet","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bergman Clinics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bergman Clinics \/ Zimmer Biomet","highestDevelopmentStatusID":"9","companyTruncated":"Bergman Clinics \/ Zimmer Biomet"},{"orgOrder":0,"company":"National Liver Institute, Egypt","sponsor":"Pharco Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"National Liver Institute, Egypt","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Liver Institute, Egypt \/ Pharco Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"National Liver Institute, Egypt \/ Pharco Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Grazoprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Grazoprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oslo University Hospital \/ Pharmacosmos AS","highestDevelopmentStatusID":"9","companyTruncated":"Oslo University Hospital \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Praxair Distribution","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gas for Inhalation","sponsorNew":"Boston Children's Hospital \/ Praxair Distribution","highestDevelopmentStatusID":"9","companyTruncated":"Boston Children's Hospital \/ Praxair Distribution"},{"orgOrder":0,"company":"Total Definer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Total Definer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Total Definer Research Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Total Definer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Obstetrix Medical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Obstetrix Medical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Obstetrix Medical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Obstetrix Medical Group \/ Undisclosed"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C","highestDevelopmentStatusID":"9","companyTruncated":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C"},{"orgOrder":0,"company":"American University of Beirut Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"LEBANON","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"American University of Beirut Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American University of Beirut Medical Center \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"American University of Beirut Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Yasoo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Aquavanta","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Yasoo Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yasoo Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yasoo Health \/ Undisclosed"},{"orgOrder":0,"company":"Fonterra Research Centre","sponsor":"Danisco | Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NEW ZEALAND","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Bifidobacterium Lactis HN019","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Fonterra Research Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fonterra Research Centre \/ Danisco | Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Fonterra Research Centre \/ Danisco | Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Taejoon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTO0303-A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Taejoon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taejoon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Taejoon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Dpt-Hb-Hib Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno","sponsor":"Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Gamma Variant Rbd-Based Arvac-Cg Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno \/ Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno \/ Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HRIG","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Human Platelets","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"I004","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Incepta Vaccine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BANGLADESH","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Ingovax ACWY","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Incepta Vaccine","highestDevelopmentStatusID":"9","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Incepta Vaccine"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pharmbio Korea","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seoul National University Hospital \/ Pharmbio Korea","highestDevelopmentStatusID":"9","companyTruncated":"Seoul National University Hospital \/ Pharmbio Korea"},{"orgOrder":0,"company":"Curadel Surgical Innovations, Inc.","sponsor":"Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nizaracianine Triflutate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Curadel Surgical Innovations, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curadel Surgical Innovations, Inc. \/ Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai","highestDevelopmentStatusID":"9","companyTruncated":"Curadel Surgical Innovations, Inc. \/ Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NTC015","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"Mucosa innovations","sponsor":"Universidad de Granada","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Mucosa innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mucosa innovations \/ Universidad de Granada","highestDevelopmentStatusID":"9","companyTruncated":"Mucosa innovations \/ Universidad de Granada"},{"orgOrder":0,"company":"Murdoch Childrens Research Institute","sponsor":"Institut Pasteur | Menzies School of Health Research | National Health and Medical Research Council, Australia | Bill & Melinda Gates Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PCV10","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Murdoch Childrens Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Murdoch Childrens Research Institute \/ Institut Pasteur | Menzies School of Health Research | National Health and Medical Research Council, Australia | Bill & Melinda Gates Foundation | GSK","highestDevelopmentStatusID":"9","companyTruncated":"Murdoch Childrens Research Institute \/ Institut Pasteur | Menzies School of Health Research | National Health and Medical Research Council, Australia | Bill & Melinda Gates Foundation | GSK"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Aix Scientifics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rescap","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloksys Life Sciences \/ Aix Scientifics","highestDevelopmentStatusID":"9","companyTruncated":"Alloksys Life Sciences \/ Aix Scientifics"},{"orgOrder":0,"company":"Vinbiocare Biotechnology Joint Stock Company","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RNA SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Vinbiocare Biotechnology Joint Stock Company","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vinbiocare Biotechnology Joint Stock Company \/ Arcturus Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Vinbiocare Biotechnology Joint Stock Company \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Seasonal Trivalent Split, Inactivated Influenza Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SWIM816","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemirna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Stemirna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins Bloomberg School of Public Health","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh | United Nations World Food Programme (WFP) | DSM Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Wheat Soy Blend","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Johns Hopkins Bloomberg School of Public Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins Bloomberg School of Public Health \/ International Centre for Diarrhoeal Disease Research, Bangladesh | United Nations World Food Programme (WFP) | DSM Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Johns Hopkins Bloomberg School of Public Health \/ International Centre for Diarrhoeal Disease Research, Bangladesh | United Nations World Food Programme (WFP) | DSM Ltd"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Varicella Vaccine","moa":"Varicella-zoster virus gH\/gL","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"London Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Drops","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"L'Oreal","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"L'Oreal","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Serum","sponsorNew":"L'Oreal \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"9","companyTruncated":"L'Oreal \/ Goldman, Butterwick, Fitzpatrick and Groff"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Christopher Bell","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Christopher Bell","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Christopher Bell"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
CTO0303-A is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Details :
Vitamin C is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Details :
Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy, Early.
Details :
ADC189 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Sponsor :
Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai
Details :
Nizaracianine Triflutate is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Sponsor :
Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai
Details :
SWIM816 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Details :
Gamma Variant Rbd-Based Arvac-Cg Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) :
Gamma Variant Rbd-Based Arvac-Cg Vaccine
Details :
IAH0968 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Details :
I004 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Details :
PIKA COVID-19 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Reset All
